TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety between docetaxel combined
with doxorubicin (epirubicin) and cyclophosphamide followed by gemcitabine combined with
cisplatin and doxorubicin (epirubicin) combined with cyclophosphamide followed by docetaxel
for high risk triple negative breast cancer predicted by the mRNA-lncRNA integrated signature
and validation the efficacy of the signature.